SCHEMBL26617175

SCHEMBL26617175

Cc1cc(-c2cccc(C(=O)NCc3cccc[n+]3[O-])c2)ccc1Cl

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ DRD4 P21917 2/20 0.48
▸ EPHX2 P34913 1/20 0.43
▸ NR1H4 Q96RI1 1/20 0.43
▸ CFD P00746 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ WDR5 P61964 2/20 0.41
▸ ERN1 O75460 1/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ ACLY P53396 1/20 0.39
▸ PPARG P37231 1/20 0.39
▸ SCN2A Q99250 1/20 0.39
▸ SCN10A Q9Y5Y9 1/20 0.39
▸ BCL2L1 Q07817 1/20 0.39
▸ MCL1 Q07820 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26617245 0.90 BCL2L1 (0.48) EPHX2NR1H4CFDERN1SMN1; SMN2
SCHEMBL26617254 0.89 EPHX2 (0.43) DRD4EPHX2NR1H4CFDERN1
SCHEMBL26617187 0.88 DRD4 (0.48) DRD4EPHX2NR1H4CFDERN1
SCHEMBL26617205 0.88 EPHX2 (0.48) DRD4EPHX2NR1H4CFDALDH1A1
SCHEMBL26617185 0.86 DRD4 (0.49) DRD4EPHX2NR1H4CFDSMN1; SMN2
SCHEMBL26617216 0.86 EPHX2 (0.49) EPHX2NR1H4CFDALDH1A1ERN1
SCHEMBL26704079 0.86 ALDH1A1 (0.43) DRD4EPHX2NR1H4CFDALDH1A1
SCHEMBL26617236 0.86 DRD4 (0.51) DRD4ALDH1A1ERN1KDM4ESMN1; SMN2
SCHEMBL26617213 0.86 EPHX2 (0.56) EPHX2NR1H4CFDALDH1A1ERN1
SCHEMBL26617195 0.85 EPHX2 (0.47) EPHX2NR1H4CFDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250333383-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2025-10-30 — — US claimed
EP-4514777-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK Biopharmaceuticals Co., Ltd. (KR) 2025-03-05 — — EP claimed
WO-2023211195-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-11-02 — — WO claimed
US-20250333383-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2025-10-30 — — US disclosed
EP-4514777-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK Biopharmaceuticals Co., Ltd. (KR) 2025-03-05 — — EP disclosed
WO-2023211195-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-11-02 — — WO disclosed
WO-2023211195-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-11-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250333383-A1 N-OXIDE COMPOUNDS AND USE THEREOF SCNN1B, SCN1B, SCN2B DRD4 1361/4885EPHX2 1625/4885NR1H4 1118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback